Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.47 |
| ▸ | FAP | Q12884 | 7/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749602 | 0.88 | DPP4 (0.53) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3744756 | 0.87 | ELOVL6 (0.40) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3742874 | 0.86 | DPP4 (0.40) | DPP4ELOVL6 | |
| SCHEMBL3802747 | 0.85 | DPP4 (0.52) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL13078897 | 0.84 | ELOVL6 (0.42) | DPP4DPP8ELOVL6 | |
| SCHEMBL3744361 | 0.84 | ELOVL6 (0.42) | DPP4DPP8ELOVL6 | |
| SCHEMBL3738589 | 0.82 | ELOVL6 (0.50) | ELOVL6 | |
| SCHEMBL8087356 | 0.82 | DPP4 (0.59) | DPP4FAPDPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL3741726 | 0.81 | DPP4 (0.58) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3741039 | 0.80 | CMA1 (0.44) | DPP4ELOVL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 26/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.